We Just Had An Epiphany
Tag: Biotech Stocks
No Bullish Trigger: Ginkgo Bioworks Should Read “Ginkgo Bio… Doesn’t Work”
Ginkgo Bioworks (DNA) has ambitious science and flashy AI rhetoric — but declining revenues, deep losses, and no insider conviction make this a tough stock to love. 🧬📉
Funds and Analysts Love BioMarin Pharmaceutical (BMRN), A Rare Combo of Value and Growth Fighting Also Rare Genetic Diseases. Should You?
BioMarin is that rare biotech: profits, pipeline, and price discipline. VOXZOGO grows, margins expand, and catalysts stack—at a surprisingly modest valuation.